BSC
ADPT icon

BOLTON SECURITIES CORPORATION’s Adaptive Biotechnologies ADPT Stock Holding History

BOLTON SECURITIES CORPORATION’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-10,000
Closed -$214K – 2240
2026
Q2 		$214K Hold
10,000
– – 0.01% 878
2026
Q1 		$139K Buy
+10,000
New +$159K 0.01% 921

Other funds holding ADPT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $294B AUM 47.59% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BOLTON SECURITIES CORPORATION's ADPT Position: Q3 2026 in Review

BOLTON SECURITIES CORPORATION sold out of Adaptive Biotechnologies (ADPT) in Q3 2026, closing a stake of 10,000 shares — an estimated $214K sold.

BOLTON SECURITIES CORPORATION first reported a position in ADPT in Q1 2026 and held it in 2 quarters. The position peaked at $214K in Q2 2026. 178 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • BOLTON SECURITIES CORPORATION reported no remaining Adaptive Biotechnologies position as of Q3 2026 after selling out during the quarter.
  • BOLTON SECURITIES CORPORATION sold 10,000 Adaptive Biotechnologies shares in Q3 2026, an estimated $214K.
  • BOLTON SECURITIES CORPORATION first reported a position in Adaptive Biotechnologies in Q1 2026 and held it in 2 quarters.
  • BOLTON SECURITIES CORPORATION's Adaptive Biotechnologies position peaked at $214K in Q2 2026.
  • 178 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on BOLTON SECURITIES CORPORATION's 13F filing for Q3 2026, filed 12 Nov 2026.